ClinicalTrials.gg
TerminatedNCT01068782Updated Feb 25, 2026Results posted

Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

A Phase 2 interventional study of Cabozantinib in Astrocytic Tumors, sponsored by Exelixis. Terminated at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Exelixis · Phase 2, Interventional, and Treatment

Why this study was terminated
Enrollment in this study was terminated for business development reasons before completing one third of the expected subject population, no formal statistical testing was performed.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Enrollment
787th of 1,155
19 · median 33
Started
2010
with 56 others
Phase 2
396 of 1,302
37 open now
Registered
416th of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 787th largest by enrollment of the 1,155 interventional ones that give a count, is one of 57 that started in 2010, is one of 396 in phase 2, and was the 416th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

This study was conducted in subjects with grade IV astrocytic tumors (a type of cancer that can occur in the brain or spinal cord) in first or second relapse.

Read the detailed description

The goal of this clinical trial is to learn if the drug cabozantinib works for people with astrocytic tumors. It also was designed to learn about the safety of cabozantinib. The main questions are:

  1. Does cabozantinib work and how well do patients tolerate the drug for over 12 weeks.
  2. Was the drug safe and how well could patients tolerate treatment for the entire treatment period.

Participants were assigned to one of the four treatment groups:

Arm 1. Take cabozantinib at a dose of 25 mg once every day (po QD) continuously until progression.

Arm 2. Take cabozantinib at a dose of 75 mg once every day continuously until progression.

Arm 3. Take cabozantinib at a dose of 125 mg once every day for 2 weeks, followed by 50 mg every day (po QD) for the remainder of the treatment period;

Arm 4. Take cabozantinib at a dose of 125 mg once every day for 2 weeks, followed by 1 week off. For the remainder of the treatment period, patients received cabozantinib at a dose of 125 mg once every day for three weeks followed by one week of rest.

03

Conditions studied

  • Astrocytic Tumors

Keywords

  • Glioblastoma
  • Glioma
  • Brain Cancer
  • Brain Tumor
  • Astrocytoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject has confirmed diagnosis at any time of grade IV astrocytic tumor as determined by the investigator. Tumor samples will be required for pathology review.
  • The subject has received prior standard radiation for any grade astrocytic tumor.
  • The subject has received prior temozolomide (Temodar) therapy
  • The subject has had one or two progressions as grade IV astrocytic tumor from any grade, as determined by investigator
  • The subject must have a qualifying brain MRI scan within a specific timeframe prior to start of study treatment
  • For subjects with recent tumor resection or , starting on study must occur a specified amount of time after the surgery and the subject must have recovered from the effects of surgery
  • The subject has a Performance Status ≥ 70% and has the ability to swallow whole capsules
  • The subject is capable of understanding the and has signed the informed consent document
  • The subject has adequate organ and marrow function
  • Sexually active subjects (male and female) must agree to use medically accepted methods of during the course of the study and for 6 months following discontinuation of study treatment
  • The subject has had no other diagnosis of (certain exceptions apply)
  • Female subjects of must have a negative pregnancy test at screening

Exclusion criteria

Exclusion Criteria:

  • The subject has received certain prior anticancer therapies within a certain amount of time before starting study treatment
  • The subject is receiving warfarin (or other coumarin derivatives) and is unable to switch to low molecular weight heparin
  • The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or CT scan. Subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin are eligible
  • The subject is unable to undergo MRI scan (eg, has pacemaker)
  • The subject has received enzyme-inducing anti-epileptic agents within a certain time prior to starting study treatment (eg, carbamazepine, phenytoin, phenobarbital, primidone)
  • The subject has not recovered to National Cancer Institute (NCI) (CTCAE) v3.0 Grade ≤ 1 from AEs (except alopecia and lymphopenia) due to surgery, or other medications that were administered prior to study start
  • The subject has evidence of unhealed wounds
  • The subject is pregnant or breast-feeding
  • The subject has serious intercurrent illness or a recent history of serious disease
  • The subject has inherited bleeding diathesis or coagulopathy (disease affecting how blood clots) with the risk of bleeding
  • The subject has a history of any medical or surgical conditions (eg, stomach or intestinal surgery or resection) that would potentially interfere with or alter gastrointestinal function
  • The subject has a history of idiopathic pulmonary fibrosis or interstitial lung disease
  • The subject has received any or any inactivated vaccine within a certain amount of time before starting study treatment
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Arm 1 - cabozantinib, 25 mg

    Starting dose of 25 mg, once a day by mouth (po QD) continuously

    Drug: Cabozantinib

  • Experimental
    Arm 2 - cabozantinib, 75 mg

    Starting dose of 75 mg, po QD, continuously

    Drug: Cabozantinib

  • Experimental
    Arm 3 - cabozantinib, 125 mg followed by 50 mg

    Starting dose of 125 mg, po QD for 2 weeks, followed by 50 mg, po QD for the remainder of the treatment period.

    Drug: Cabozantinib

  • Experimental
    Arm 4 - cabozantinib, 125 mg

    Initially, the starting dose was 125 mg, po QD for 2 weeks, followed by 1 week off. For the remainder of the treatment, the dosing frequency was reduced to 125 mg, po QD every 3 weeks, followed by 1 week of rest for the remainder of the treatment period.

    Drug: Cabozantinib

Interventions

06

What researchers measure

Primary outcomes

  1. Randomized Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE was defined as any event with an onset date on or after the date of first dose of study drug, or any ongoing event on the date of first dose that worsened in severity after the date of first dose. TEAEs were defined as AEs that started on or after the first administration of study drug up to the date of last dose plus 30 days. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'.

    Time frame: Up to 13 months

  2. Expansion Phase: Objective Response Rate (ORR)

    ORR was defined as the number of participants for whom the best overall response at the time of data cutoff is confirmed complete response (CR) or confirmed partial response (PR) as assessed per modified Response Assessment in Neuro-Oncology (RANO) criteria. CR = Disappearance of all enhancing target lesion(s) and no glucocorticoids (other than a physiologic replacement dose of a maximum of 1.2 mg dexamethasone equivalent dose per day) taken for the 5 days immediately preceding the date of the current magnetic resonance imaging (MRI). PR = ≥50% decrease in the sum of the products of perpendicular diameters of all target enhancing lesions on the current MRI scan compared to the baseline MRI scan and glucocorticoids stable or decreased. The sponsor terminated the study early due to business reasons before entering the expansion phase. As such, no data were collected for efficacy analyses.

    Time frame: Up to 13 months

Secondary outcomes

  1. Expansion Phase: Progression Free Survival at 6 Months as Per Independent Radiology Facility

    Progression-free survival at 6 months (PFS6) was defined as the proportion of participants alive and progression-free 182 days after Study Day 1. The sponsor terminated the study early due to business reasons before entering the expansion phase. As such, no data were collected for efficacy analyses.

    Time frame: Month 6

07

Results

Posted Feb 25, 2026
Limitations and caveats
The enrollment in this study was terminated for business development reasons before enrolling one third of the expected participant population. No efficacy data were collected and limited safety data were collected.

Participant flow

The enrollment in this study was terminated early for business development reasons.

Participant flow — Overall Study
MilestoneArm 1 - Cabozantinib, 25 mgArm 2 - Cabozantinib, 75 mgArm 3 - Cabozantinib, 125 mgArm 4 - Cabozantinib, 125 mg, QD for 2 Weeks, Followed by 1 Week Off
Started5464
Completed0000
Not completed5464
Withdrew: Business decision5464

Outcome measures

PrimaryRandomized Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

An AE was defined as any event with an onset date on or after the date of first dose of study drug, or any ongoing event on the date of first dose that worsened in severity after the date of first dose. TEAEs were defined as AEs that started on or after the first administration of study drug up to the date of last dose plus 30 days. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'.

Time frame:
Up to 13 months
Reported as:
Count of participants · Participants
Randomized Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsArm 1Arm 2Arm 3Arm 4
Randomized Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs)5364
PrimaryExpansion Phase: Objective Response Rate (ORR)

ORR was defined as the number of participants for whom the best overall response at the time of data cutoff is confirmed complete response (CR) or confirmed partial response (PR) as assessed per modified Response Assessment in Neuro-Oncology (RANO) criteria. CR = Disappearance of all enhancing target lesion(s) and no glucocorticoids (other than a physiologic replacement dose of a maximum of 1.2 mg dexamethasone equivalent dose per day) taken for the 5 days immediately preceding the date of the current magnetic resonance imaging (MRI). PR = ≥50% decrease in the sum of the products of perpendicular diameters of all target enhancing lesions on the current MRI scan compared to the baseline MRI scan and glucocorticoids stable or decreased. The sponsor terminated the study early due to business reasons before entering the expansion phase. As such, no data were collected for efficacy analyses.

Time frame:
Up to 13 months

No measurements were reported for this outcome.

SecondaryExpansion Phase: Progression Free Survival at 6 Months as Per Independent Radiology Facility

Progression-free survival at 6 months (PFS6) was defined as the proportion of participants alive and progression-free 182 days after Study Day 1. The sponsor terminated the study early due to business reasons before entering the expansion phase. As such, no data were collected for efficacy analyses.

Time frame:
Month 6

No measurements were reported for this outcome.

Adverse events

Collected over Up to 13 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 10/5 (0%)2/5 (40%)5/5 (100%)
Arm 20/4 (0%)1/4 (25%)3/4 (75%)
Arm 30/6 (0%)1/6 (16.7%)6/6 (100%)
Arm 40/4 (0%)1/4 (25%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventArm 1Arm 2Arm 3Arm 4
Intracranial Tumour HaemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/50/40/61/4
Mental Status ChangesPsychiatric disorders0/51/40/60/4
NauseaGastrointestinal disorders0/51/40/60/4
VomitingGastrointestinal disorders0/51/40/60/4
DehydrationMetabolism and nutrition disorders0/51/40/60/4
MigraineNervous system disorders1/50/40/60/4
ConvulsionNervous system disorders1/50/40/60/4
Basal Ganglia InfarctionNervous system disorders0/50/41/60/4
Clostridial InfectionInfections and infestations0/50/41/60/4
Most frequent other events
Showing 10 of 113
Most frequent other events
EventArm 1Arm 2Arm 3Arm 4
FatigueGeneral disorders3/53/45/62/4
NauseaGastrointestinal disorders3/53/43/62/4
DiarrhoeaGastrointestinal disorders1/52/43/62/4
Tinea pedisInfections and infestations0/50/40/62/4
Blood thyroid stimulating hormone increasedInvestigations0/52/41/61/4
HeadacheNervous system disorders2/50/43/62/4
DepressionPsychiatric disorders0/52/42/61/4
HypertensionVascular disorders1/51/41/62/4
Lipase increasedInvestigations2/50/40/61/4
FlatulenceGastrointestinal disorders0/50/42/60/4

Baseline characteristics

Age, Customized
Age, Customized(Participants)Arm 1 - Cabozantinib, 25 mgArm 2 - Cabozantinib, 75 mgArm 3 - Cabozantinib, 125 mg, Followed by 50 mg, po QD for the Remainder of the Treatment Period.Arm 4 - Cabozantinib, 125 mg, QD for 2 Weeks, Followed by 1 Week OffTotal
18 - <25 years00000
25 - <45 years10304
45 - <65 years441413
65 years and Over00202
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1 - Cabozantinib, 25 mgArm 2 - Cabozantinib, 75 mgArm 3 - Cabozantinib, 125 mg, Followed by 50 mg, po QD for the Remainder of the Treatment Period.Arm 4 - Cabozantinib, 125 mg, QD for 2 Weeks, Followed by 1 Week OffTotal
Female41139
Male135110
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1 - Cabozantinib, 25 mgArm 2 - Cabozantinib, 75 mgArm 3 - Cabozantinib, 125 mg, Followed by 50 mg, po QD for the Remainder of the Treatment Period.Arm 4 - Cabozantinib, 125 mg, QD for 2 Weeks, Followed by 1 Week OffTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White545418
More than one race00101
Unknown or Not Reported00000
08

Study locations

19 sites
  • Birmingham, Alabama 35294, United States
  • Encinitas, California 92024, United States
  • Pleasant Hill, California 94523, United States
  • Chicago, Illinois 60611, United States
  • Chicago, Illinois 60637, United States
  • Boston, Massachusetts 02115, United States
  • Detroit, Michigan 48202, United States
  • Minneapolis, Minnesota 55407, United States
  • Amherst, New York 14226, United States
  • Rochester, New York 14642, United States
  • Cleveland, Ohio 44195, United States
  • Hershey, Pennsylvania 17033, United States
  • Dallas, Texas 75246, United States
  • Dallas, Texas 75426, United States
  • San Antonio, Texas 78229, United States
  • Charlottesville, Virginia 22908, United States
  • Seattle, Washington 98122, United States
  • Calgary, Alberta, Canada
  • Montreal, Quebec, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of May 2011 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2026, 14 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2010
First posted
Feb 15, 2010
Start
Apr 2010
Primary completionActual
May 2011
CompletionActual
Oct 2013
Results first posted
Feb 25, 2026
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01068782
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Feb 15, 2010
Start date
Apr 2010
Primary completion
May 2011
Completion
Oct 2013
Results posted
Feb 25, 2026
Last update
Feb 25, 2026

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion